Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 305.82M shares rose 3.0% year over year, behind the +5.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.0% toward the trailing-twelve-month pace of +5.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
305.82M+1.3% QoQ
Last fiscal yearDec 2025
299.96M+4.0% YoY
LTMMar 2026
302.18M+5.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.0%——
1 year+4.0%——
3-year CAGR+10.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
299.96M USD
Year-over-year change
+4.0%
4-year CAGR
+10.1%

Weighted Avg Shares (Diluted) vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's LTM Mar 2026 weighted avg shares (diluted) of 302.18M shares is the highest of the 3 companies compared; the peer median is 177.74M shares.
  • Its year-over-year change of +5.2% is the 2nd highest of 3, against a peer median of +14.2%.
  • Over three fiscal years its annual growth of +10.1% compares with a peer median of +6.1%.
PACB Competitors Peer median
Weighted Avg Shares (Diluted) for PACB and competitors
Company Period LTM YoY 3-year CAGR
PACBPacific Biosciences of California, Inc.LTM Mar 2026302.18M +5.2%+10.1%
QSIQuantum-Si incorporatedLTM Mar 2026201.73M +31.6%+12.4%
ILMNIllumina, Inc.LTM Jun 2026153.75M -3.3%-0.2%
Peer median (excluding PACB) 177.74M+14.2%+6.1%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.51M128.3M200.52M154.01M160.01M
Cost of Revenue71.65M79.27M147.74M116.73M109.33M
Gross Profit58.86M49.04M52.78M37.28M50.67M
Gross Margin45.1%38.2%26.3%24.2%31.7%
Research & Development112.9M193M187.17M134.92M97.31M
Selling, General & Admin124.12M160.85M169.82M175.02M141.49M
Operating Expenses269.3M356.23M387.25M511.6M608.24M
Depreciation & Amortization11.59M17.32M32.69M53.35M504.91M
EBITDA(250.76M)(282.24M)(271.13M)(242.77M)(34.2M)
EBITDA Margin-192.1%-220.0%-135.2%-157.6%-21.4%
Operating Income(210.44M)(307.2M)(334.47M)(474.31M)(557.56M)
Operating Margin-161.2%-239.4%-166.8%-308.0%-348.5%
Interest Income00000
Interest Expense12.53M14.69M14.34M13.41M6.95M
Other Income / Expenses(64.44M)(7.05M)16.31M164.78M11.5M
Income Before Tax(274.87M)(314.25M)(318.16M)(309.54M)(546.06M)
Pre-Tax Margin-210.6%-244.9%-158.7%-201.0%-341.3%
Income Tax Expense(93.65M)0(11.42M)316K318K
Net Income(181.22M)(314.25M)(306.74M)(309.85M)(546.38M)
Net Margin-138.9%-244.9%-153.0%-201.2%-341.5%
EPS (Basic)(0.89)(1.40)(1.21)(1.13)(1.82)
EPS (Diluted)(0.89)(1.40)(1.21)(1.07)(1.82)
Weighted Avg Shares203.62M224.55M253.63M274.49M299.96M
Weighted Avg Shares (Diluted)204.14M224.55M253.63M288.37M299.96M

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.